AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER 2024 (In Lakhs)

	PARTICULARS	QUARTER ENDED					Year Ended (Audited)
		31.12.2024	30.09.2024	31.12.2023	Period Ended (UnAudited) 31.12.2024	Period Ended (UnAudited) 31.12.2023	31.03.2024
I	**Income**						
	Revenue from operations	3,403.46	2,572.44	2,005.04	8,541.75	6,053.30	8,011.46
	Other income	38.63	30.96	157.43	73.26	193.65	219.33
	Total income from operations	**3,442.09**	**2,603.40**	**2,162.47**	**8,615.01**	**6,246.95**	**8,230.79**
II	**Expenses**						
	Cost of Material Consumed	2,924.11	2,247.25	1,813.35	7,456.33	5,459.95	6,986.34
	Change In Inventories	(24.21)	9.41	29.82	(23.52)	26.64	48.65
	Employee benefit expenses	89.13	70.31	61.40	216.72	166.11	180.05
	Finance costs	6.83	5.90	12.08	27.75	44.65	55.69
	Depreciation and amortization expenses	23.75	22.56	21.34	71.25	63.59	87.42
	Payment to NSE						
	Other expenses	321.50	168.50	166.21	624.74	336.23	573.03
	Total expenses	**3,341.11**	**2,523.93**	**2,104.20**	**8,373.27**	**6,097.17**	**7,931.18**
III	**Profit/(Loss) before exceptional items and tax**	**100.98**	**79.47**	**58.27**	**241.74**	**149.78**	**299.61**
IV	**Exceptional items**						
V	**Profit/(Loss) before tax**	**100.98**	**79.47**	**58.27**	**241.74**	**149.78**	**299.61**
VI	**Tax expenses**						
	a) Current tax	22.22	19.07	15.14	53.18	27.64	87.50
	b) Deferred tax	5.74	-1.11362298	(0.85)	5.74	(2.50)	4.01
	b) Mat Credit						
VII	**Net Profit/(Loss) for the period/year**	**73.02**	**61.51**	**43.98**	**182.82**	**124.64**	**208.10**
VIII	**Other comprehensive income (net of tax)**				-		
	loss:	**2.14**	**54.14**	**-**	**56.28**	**(162.77)**	**(103.22)**
	Total other comprehensive income						
IX	**Total comprehensive income for the period/year (VII+VIII)**	**75.16**	**115.65**	**43.98**	**239.10**	**(38.13)**	**112.09**
X	**Paid-up equity share capital (face value of the share shall be indicated)**	**3,444.87**	**3,444.87**	**1,752.27**	**3,444.87**	**1,752.27**	**1,752.27**
XI	**Other equity (excluding revaluation reserve)**	**5,288.88**	**5,167.57**	**2,361.76**	**5,288.88**	**2,361.76**	2,518.51

AJOONI BIOTECH LTD. MOHALI

XII	EPS in Rs. (Face Value of Rs.2/- each)*				-		
	-Basic	0.04	0.04	0.25	0.07	0.71	0.25
	-Diluted	0.04	0.04	0.25	0.07	0.71	0.25

Notes:

1. The above results are as per Regulation 33 of the SEBI (LODR) Regulations, 2015 as amended and have been taken on record by Board of Directors at its meeting held on 13.02.2025 after being reviewed by the Audit Committee.

2. The company is having single segment in accordance with IND AS 108 "operating segments". and therefore segment reporting is not applicable to the Company.

3. Due to re-grouping of schedules, and as per applicability of IND-AS, there has been a difference in the figures as reported earlier.

For Ajooni Biotech Limited

AJOONI BIOTECH LTD. MOHALI

Place : Mohali
Date : 13.02.2025

Jasjot Singh
Managing Director
DIN: 01937631

Ajooni biotech

AJOONI BIOTECH LIMITED

Regd. Office : D-118, Industrial Area, Phase-VII, Mohali-160055 (Pb.)
Corporate Office : H.No. 1769, Phase 3B2, Mohali-160059
Phone : 0172-5020758-69 Website : www.ajoonibiotech.com
E-mail : ajooni.biotech@gmail.com / info@ajoonibiotech.com
CIN: L85190PB2010PLC040162

AJOONI BIOTECH LIMITED

CIN : L85190PB2010PLC040162

Statement of Assets and Liabilities

For the Year ended on 31st december 2024

in Rs. (Lakhs)

PARTICULARS	31st december 2024	31ST MARCH 2024
I. ASSETS		
(1) Non - Current Assets		
a) Property, Plant and Equipment	1,146.86	1,031.89
b) Capital Work In Progress	0.00	92.45
c) Investment Property		-
d) Goodwill		-
e) Other Intangible Assets		-
f) Intangible Assets Under Development		-
g) Biological Assets other than Bearer Plants		-
h) Financial Assets		
(1) Investments	437.36	213.63
(2) Trade Receivables		-
(3) Loans		-
(4) Other Financial Assets		
i) Deffered Tax Asset (net)	36.96	31.22
j) Other Non Current Asset	240.11	150.00
(2) Current Assets		
a) Inventories	2,089.27	1,536.73
b) Financial Assets		
(1) Investments		
(2) Trade Receivables	2,179.63	1,295.94
(3) Cash & Cash Equivalent	1,759.22	42.82
(4) Bank Balances other than (iii) above		
(5) Loans and Advances	1,458.61	351.42
(6) Other Financial Asset		0.00

AJOONI BIOTECH LTD. MOHALI

c) Current Tax Assets (net)		-
d) Other Current Asset	18.92	5.93
TOTAL	9,366.94	4,752.04
II EQUITY AND LIABILITIES		
(1) Equity		
a)Equity Share Capital	3,444.87	1,752.27
b) Other Equity	5,288.88	2,518.51
(2) Non-Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	206.15	168.20
(2) Trade Payables		
(3) Other Financial Liabilties		
b) Employee Benefit Obligations	13.04	11.99
c) Deferred Tax Liability (net)		-
d) Other Non Current Liability		-
(3) Current Liabilities		
a) Financial Liabilities		
(1) Borrowings	0.00	48.57
(2) Trade Payables	295.85	158.45
(3) Other Financial Liabilities		
b) Employee Benefit Obligations	1.48	1.05
c) Other Current Liabilities	63.49	5.48
d) Current tax liabilities (Net)	53.18	87.50
TOTAL	9,366.94	4,752.04

Place : Mohali
Date : 13.02.2025

For Ajooni Biotech Limited

Jasjot Singh
Managing Director
DIN: 01937631

AJOONI BIOTECH LTD MOHALI

NARINDER KUMAR & COMPANY
CHARTERED ACCOUNTANTS

SCO 65-B (1st Floor) City Heart,
Kharar Chandigarh Road,
Kharar, SAS Nagar Mohali-140301
Mobile : 98154 50065
Email : nkgargca@yahoo.co.in

Ref. No. .....

Limited Review Report

Dated .....

Review Report to Board of Directors of M/s Ajooni Biotech Limited.

We have reviewed the accompanying statement of unaudited financial results of M/s Ajooni Biotech Limited having Regd. office at D-118, Industrial Area, Phase-VII, Mohali Punjab-160055. for the period ended 31st December, 2024.(the Statement) attached herewith , being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and disclosure requirements) regulations 2015 (as amended) , Including relevant circulars issued by the Securities and Exchange Board of India (SEBI) from time to Time.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For NARINDER KUMAR AND COMPANY
Chartered Accountants

NARINDER KUMAR & COMPANY S.C.O. 65-B (1st Floor) City Heart Kharar-Chandigarh Road Kharar, Mohali 140301 FRN-0030737N Chartered Accountants

(NARINDER KUMAR GARG)
PARTNER
M.NO-080287

Date:- 13.02.2025
UDIN:- 25080287BMLIQF1154